EMA Refused: Elevidys (delandistrogene moxeparvovec) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency refused to grant marketing authorization for Elevidys (delandistrogene moxeparvovec) from Roche Registration GmbH for Duchenne mus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Elevidys (delandistrogene moxeparvovec)

Snippet

Status: Refused. Therapeutic area: Muscular Dystrophy, Duchenne. MAH: Roche Registration GmbH. Decision date: 24/09/2025. Orphan medicine